Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06377527 · ClinicalTrials.gov registry record
Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)
A clinical trial of Mesonephric-like Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT06377527: Recruiting study of Mesonephric-like Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
NCT06377527 is a study of Mesonephric-like Adenocarcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 2,000 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06377527, a study of Mesonephric-like Adenocarcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
To develop a database of medical information about patients with MLA in an effort to increase our understanding of the characteristics of MLA, which is the rarest form of endometrial carcinoma.
Primary Outcome
The goal of this data collection study is to develop a database (i.e. a registry/repository) of medical information about patients with MLA in an effort to increase our understanding of the characteristics of MLA, which is the rarest form of endometrial carcinoma.
Conditions Studied
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2024-07-10 |
| Est. Completion | 2037-12-28 |
What NCT06377527 shows while recruiting
NCT06377527 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Mesonephric-like Adenocarcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT06377527 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06377527 about?
NCT06377527 is a clinical study titled "Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)". To develop a database of medical information about patients with MLA in an effort to increase our understanding of the characteristics of MLA, which is the rarest form of endometrial carcinoma.
What is the current status of trial NCT06377527?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2024-07-10. Estimated completion is 2037-12-28.
What conditions does trial NCT06377527 study?
This clinical trial studies the following conditions: Mesonephric-like Adenocarcinoma.
Who is sponsoring clinical trial NCT06377527?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06377527 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI